Skip to content

Inhibrx Biosciences

US · INBX #3022 by market cap Listed 2024
68.97 -5.36 -7.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio -14.28 Cheap vs history 29th percentile
5-year average 5.71
P/E ratio -9.19 Cheap vs history 23rd percentile
5-year average -4.33 · forward -8.32
P/S ratio 612.99 In line with history 41st percentile
5-year average 675.57 · forward 84.84 · #343 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Inhibrx Biosciences (INBX) 1.02B -7.61 -11.86 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value109.28 Economic moatNone UncertaintyVery High

Trading 58.4% below Morningstar's fair value estimate.

Fair value

Inhibrx Biosciences Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 24% discount to our quantitative fair value estimate of $109.28 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet strengthens our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its long term debt to assets ratio, which lies in the top 1% compared with peers globally. The firm has a high level of long-term debt relative to its asset base, which can signal significant investment in the business or a pending merger. In either case, it may suggest future growth in cash flows. We believe this is a sign that shares could be undervalued.

Conversely, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, falls in the top 50% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Inhibrx Biosciences discussion 0 comments

Add a comment